{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:57:39Z","timestamp":1793361459869,"version":"4.5.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-XL\/BCL2 inhibitor, may allow targeting of both BCL2 and BCL-XL without dose-limiting thrombocytopenia associated with navitoclax monotherapy. The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase I dose-escalation study (NCT03181126) in pediatric and adult patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia or lymphoblastic lymphoma. Forty-seven patients received treatment. A recommended phase II dose of 50 mg navitoclax for adults and 25 mg for patients &amp;lt;45 kg with 400 mg adult-equivalent venetoclax was identified. Delayed hematopoietic recovery was the primary safety finding. The complete remission rate was 60%, including responses in patients who had previously received hematopoietic cell transplantation or immunotherapy. Thirteen patients (28%) proceeded to transplantation or CAR T-cell therapy on study. Venetoclax with navitoclax and chemotherapy was well tolerated and had promising efficacy in this heavily pretreated patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this phase I study, venetoclax with low-dose navitoclax and chemotherapy was well tolerated and had promising efficacy in patients with relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma. Responses were observed in patients across histologic and genomic subtypes and in those who failed available therapies including stem cell transplant.<\/jats:p>\n                    <jats:p>See related commentary by Larkin and Byrd, p. 1324.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 1307<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-20-1465","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T12:10:25Z","timestamp":1613477425000},"page":"1440-1453","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":291,"title":["Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma"],"prefix":"10.1158","volume":"11","author":[{"given":"Vinod A.","family":"Pullarkat","sequence":"first","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-5118","authenticated-orcid":false,"given":"Norman J.","family":"Lacayo","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics \u2013 Hematology\/Oncology, Stanford University, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9885-3527","authenticated-orcid":false,"given":"Jeffrey E.","family":"Rubnitz","sequence":"additional","affiliation":[{"name":"4Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee."},{"name":"5Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-7334","authenticated-orcid":false,"given":"Ashish","family":"Bajel","sequence":"additional","affiliation":[{"name":"6Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8497-3138","authenticated-orcid":false,"given":"Theodore W.","family":"Laetsch","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, The University of Texas Southwestern Medical Center\/Children's Health, Dallas, Texas."},{"name":"8Division of Oncology, Children's Hospital of Philadelphia\/University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica","family":"Leonard","sequence":"additional","affiliation":[{"name":"9Department of Hematology\/Medical Oncology, Oregon Health Sciences University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-3655","authenticated-orcid":false,"given":"Susan I.","family":"Colace","sequence":"additional","affiliation":[{"name":"10Pediatrics \u2013 Hematology and Oncology, Nationwide Children's Hospital, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-8974","authenticated-orcid":false,"given":"Seong Lin","family":"Khaw","sequence":"additional","affiliation":[{"name":"11Royal Children's Hospital, Victoria, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun A.","family":"Fleming","sequence":"additional","affiliation":[{"name":"12Department of Hematology, The Alfred Hospital and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Mattison","sequence":"additional","affiliation":[{"name":"13University of Wisconsin Carbone Cancer Center, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Norris","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Opferman","sequence":"additional","affiliation":[{"name":"15Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7626-4043","authenticated-orcid":false,"given":"Kathryn G.","family":"Roberts","sequence":"additional","affiliation":[{"name":"16Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-5312","authenticated-orcid":false,"given":"Yaqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"16Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxu","family":"Qu","sequence":"additional","affiliation":[{"name":"16Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Badawi","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Schmidt","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tong","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Pesko","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A.","family":"Ross","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Rosenwinkel","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Young","family":"Kim","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-6204","authenticated-orcid":false,"given":"Amanda","family":"Jacobson","sequence":"additional","affiliation":[{"name":"17AbbVie Inc., North Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[{"name":"16Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-1574","authenticated-orcid":false,"given":"Thomas B.","family":"Alexander","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, The University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"19The University of Chicago Medicine, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"2022060711091434600_bib1","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060711091434600_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060711091434600_bib3","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060711091434600_bib4","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/cncr.23919","article-title":"Outcome of adults with acute lymphocytic leukemia after second salvage therapy","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"2022060711091434600_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clml.2017.05.016","article-title":"Prognostic factors and outcomes of adult lymphoblastic lymphoma in the United States","volume":"17","author":"El-Fattah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022060711091434600_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2022060711091434600_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2022060711091434600_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","article-title":"Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"10","author":"Kadia","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2022060711091434600_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2017","journal-title":"Cell Death Differ"},{"key":"2022060711091434600_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2022060711091434600_bib11","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"2022060711091434600_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","article-title":"The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs","volume":"77","author":"High","year":"2010","journal-title":"Mol Pharmacol"},{"key":"2022060711091434600_bib13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","article-title":"Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo","volume":"110","author":"Kang","year":"2007","journal-title":"Blood"},{"key":"2022060711091434600_bib14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/pbc.21433","article-title":"Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program","volume":"50","author":"Lock","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"2022060711091434600_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fonc.2019.00192","article-title":"The role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome","volume":"9","author":"McBride","year":"2019","journal-title":"Front Oncol"},{"key":"2022060711091434600_bib16","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia","volume":"79","author":"Diaz-Flores","year":"2019","journal-title":"Cancer Res"},{"key":"2022060711091434600_bib17","doi-asserted-by":"crossref","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022060711091434600_bib18","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060711091434600_bib19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"2022060711091434600_bib20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"key":"2022060711091434600_bib21","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"key":"2022060711091434600_bib22","first-page":"PO.18.00127","article-title":"First report of clinical response to venetoclax in early T-cell precursor acute lymphoblastic leukemia","volume":"2","author":"Numan","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2022060711091434600_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022060711091434600_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060711091434600_bib25","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Safety, pharmacokinetics, pharmacodynamics, and activity of navitoclax, a targeted high affinity inhibitor of BCL-2, in lymphoid malignancies","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060711091434600_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"2022060711091434600_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","article-title":"PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia","volume":"51","author":"Gu","year":"2019","journal-title":"Nat Genet"},{"key":"2022060711091434600_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"2022060711091434600_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1078155217701291","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"24","author":"Christ","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2022060711091434600_bib30","first-page":"600","article-title":"Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia","volume":"7","author":"Earl","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"key":"2022060711091434600_bib31","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"2022060711091434600_bib32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"2022060711091434600_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060711091434600_bib34","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"2022060711091434600_bib35","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060711091434600_bib36","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"2022060711091434600_bib37","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"key":"2022060711091434600_bib38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"2022060711091434600_bib39","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/sj.leu.2402141","article-title":"The growth of highly proliferative acute lymphoblastic leukemia may be independent of stroma and\/or angiogenesis","volume":"15","author":"Schneider","year":"2001","journal-title":"Leukemia"},{"key":"2022060711091434600_bib40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s00018-008-8637-6","article-title":"Mcl-1 is a potential therapeutic target in multiple types of cancer. Cellular and molecular life sciences","volume":"66","author":"Akgul","year":"2009","journal-title":"CMLS"},{"key":"2022060711091434600_bib41","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022060711091434600_bib42","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022060711091434600_bib43","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"2022060711091434600_bib44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1515\/hsz-2016-0107","article-title":"iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry","volume":"397","author":"Ryan","year":"2016","journal-title":"Biol Chem"},{"key":"2022060711091434600_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2022060711091434600_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2022060711091434600_bib47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","article-title":"Quality control and preprocessing of metagenomic datasets","volume":"27","author":"Schmieder","year":"2011","journal-title":"Bioinformatics"},{"key":"2022060711091434600_bib48","first-page":"011650 2014","article-title":"FusionCatcher \u2013 a tool for finding somatic fusion genes in paired-end RNA-sequencing data","author":"Nicorici","journal-title":"bioRxiv"},{"key":"2022060711091434600_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2022060711091434600_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/6\/1440\/3104967\/1440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/6\/1440\/3104967\/1440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T07:18:36Z","timestamp":1654586316000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/6\/1440\/666591\/Venetoclax-and-Navitoclax-in-Combination-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,16]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1465","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22540348.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22540348","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6549358.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549358","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}